In patients with atrial fibrillation who were unable to receive warfarin for any reason, the use of apixaban reduced the risk of stroke and systemic embolism when compared to aspirin. Study Rundown: Atrial fibrillation is a common arrhythmia that increases the risk of stroke and. AVERROES has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. AVERROES. Apixaban Versus ASA. To Reduce the Risk Of Stroke. Coordinated by Population Health Research institute. Hamilton, Ontario, Canada. Sponsors.
|Published (Last):||19 December 2006|
|PDF File Size:||8.30 Mb|
|ePub File Size:||16.23 Mb|
|Price:||Free* [*Free Regsitration Required]|
Presented as apixaban vs. Retrieved from ” http: Assessment that patient would be unable or unlikely to adhere to restrictions on factors such as alcohol and diet; Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: To get the best experience using our website we averroee that you upgrade to a newer version.
J Am Coll Cardiol ; Dual therapy decreased rates of major vascular events at cost of increased major bleeding. Other characteristics indicating avreroes of stroke too low to warrant treatment with VKAs; Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.
AVERROES – Wiki Journal Club
In April the Data and Safety Monitoring Board recommended early study termination because of clear benefit in favor of apixaban. Analyses are to time of first event.
Did you know that your browser is out of date? Adverse event not related to bleeding during VKA therapy; 3. Concurrent medications whose metabolism could be affected by VKAs; 9.
Notes to editor Correspondence: Usable articles Cardiology Neurology. This proportion was similar for both academic and community hospitals.
The AVERROES Trial – Clinical Implications
Its role in prevention of stroke in patients unsuitable for VKA therapy, but maintained on aspirin therapy, avrroes unknown. The trial was terminated early given a treatment benefit with apixaban. Strengths Strong points and important messages of the study are: Sign in to My ESC.
Concurrent medications that could alter activity of VKAs; 8. ESC sub specialties communities. Assessment that INR could not or was unlikely to be measured at requested vaerroes 5. In such patients, aspirin plus clopidogrel reduced the rate of major vascular events, in particular stroke, vs. Based on the indirect comparison with ACTIVE A, one should conclude that apixaban is, at the time of writing, the best alternative to aspirin ever found in patients deemed unsuitable for VKAs.
All apixaaban reasons can be grouped in three broad categories: Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Mortality rates were 3. Averores may question each of these choices: In patients with atrial fibrillation thought to be unsuitable for anticoagulation with a vitamin K antagonist, does apixaban reduce risk for stroke or systemic embolism when compared to aspirin?
The AVERROES Trial – Clinical Implications
This page was last modified on 3 Decemberat In addition, patients could not be receiving VKA therapy, either because it had been demonstrated unsuitable in their case or because it was expected to be unsuitable.
The reasons that VKA therapy was unsuitable for the patient had to be documented in the study case report forms. Dabigatran versus warfarin in patients with atrial fibrillation. AVERROES on the other hand has shown that the new oral anti-Xa inhibitor apixaban averrows superior to aspirin in apixabah of efficacy, with surprisingly similar safety.
There were 44 1. To reduce the burden of cardiovascular disease. Apixaban is, at the time of writing, the best alternative to aspirin in patients deemed unsuitable for vitamin K antagonists. VKA therapy not recommended by the physician; Apixaban in Patients with Atrial Fibrillation. We will here briefly discuss the clinical implications of the trial. Patients were eligible if they were 50 years of age or older and if they had atrial fibrillation that had been documented in the 6 months prior to enrollment or by lead electrocardiography on the day of screening.
There were 51 primary outcome events in those randomised to apixaban 1.
Eur Heart J ; Read your latest personalised notifications Sign in No account yet? It has multiple theoretical benefits over VKA therapy including less intensive monitoring and fewer drug interactions. The New England Journal of Medicine. The primary outcome was stroke or systemic embolism.